(ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than April 6, 2012.

Dated: January 26, 2012.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2012–2581 Filed 2–3–12; 8:45 am]

BILLING CODE 4410–09–P

## DEPARTMENT OF JUSTICE

# **Drug Enforcement Administration**

#### Manufacturer of Controlled Substances; Notice of Registration

By Notice dated September 28, 2011, and published in the **Federal Register** on October 7, 2011, 76 FR 62450, Cody Laboratories, Inc., 601 Yellowstone Avenue, Cody, Wyoming 82414, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Dihydromorphine (9145)	Ι
Amphetamine (1100)	II
Methamphetamine (1105)	11
Amobarbital (2125)	11
Pentobarbital (2270)	11
Secobarbital (2315)	11
Phenylacetone (8501)	11
Cocaine (9041)	11
Codeine (9050)	11
Dihydrocodeine (9120)	11
Oxycodone (9143)	II
Hydromorphone (9150)	II
Diphenoxylate (9170)	II
Ecgonine (9180)	II
Hydrocodone (9193)	11
Meperidine (9230)	II
Methadone (9250)	11
Morphine (9300)	11
Oxymorphone (9652)	II
Alfentanil (9737)	П
Remifentanil (9739)	II
Sufentanil (9740)	II
Fentanyl (9801)	II

The company plans to manufacture the listed controlled substances in bulk for sale to its customers.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Cody Laboratories, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Cody Laboratories, Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: January 26, 2012.

# Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2012–2582 Filed 2–3–12; 8:45 am] BILLING CODE 4410-09–P

# DEPARTMENT OF JUSTICE

#### **Drug Enforcement Administration**

### Manufacturer of Controlled Substances; Notice of Registration

By Notice dated October 20, 2011, and published in the **Federal Register** on October 28, 2011, 76 FR 66994, Research Triangle Institute, Hermann Building, East Institute Drive, P.O. Box 12194, Research Triangle, North Carolina 27709, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Marihuana (7360)	
Cocaine (9041)	

The Institute will manufacture marihuana, and cocaine derivatives for use by their customers in analytical kits, reagents, and reference standards as directed by the National Institute on Drug Abuse.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Research Triangle Institute to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Research Triangle Institute to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of

the basic classes of controlled substances listed.

Dated: January 26, 2012.

#### Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2012–2585 Filed 2–3–12; 8:45 am]

BILLING CODE 4410–09–P

#### DEPARTMENT OF JUSTICE

### **Drug Enforcement Administration**

# Manufacturer of Controlled Substances; Notice of Registration

By Notice dated September 28, 2011, and published in the **Federal Register** on October 7, 2011, 76 FR 62449, Johnson Matthey Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, New Jersey 08066–1742, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Diphenoxylate (9170), a basic class of controlled substance listed in schedule II.

The company plans to manufacture the listed controlled substance for sale in bulk to its customers for formulation into finished pharmaceuticals.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Johnson Matthey Inc. to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Johnson Matthey Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed.

Dated: January 26, 2012.

## Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2012–2589 Filed 2–3–12; 8:45 am] BILLING CODE 4410–09–P